Mark Searcey

Mark Searcey

University of East Anglia

H-index: 31

Europe-United Kingdom

About Mark Searcey

Mark Searcey, With an exceptional h-index of 31 and a recent h-index of 14 (since 2020), a distinguished researcher at University of East Anglia, specializes in the field of Medicinal chemistry.

His recent articles reflect a diverse array of research interests and contributions to the field:

Suramin: Effectiveness of analogues reveals structural features that are important for the potent trypanocidal activity of the drug

Borylation via Iridium catalysed CH activation: a new concise route to duocarmycin derivatives

Peptide inhibitors of the dyskerin/dyskerin protein-protein interaction, a cancer target highlighted by Dyskeratosis Congenita mutations in ribonucleoproteins of telomerase.

Light-Activated Azobenzene Peptide Inhibitor of the PD-1/PD-L1 Interaction

The development of potent, competitive CXCR4 antagonists for the prevention of cancer metastasis

Junctions in DNA: underexplored targets for therapeutic intervention

Structural basis of the negative allosteric modulation of 5-BDBD at human P2X4 receptors

Taspine is a natural product that suppresses P2X4 receptor activity via phosphoinositide 3‐kinase inhibition

Mark Searcey Information

University

Position

___

Citations(all)

2552

Citations(since 2020)

814

Cited By

1964

hIndex(all)

31

hIndex(since 2020)

14

i10Index(all)

63

i10Index(since 2020)

27

Email

University Profile Page

Google Scholar

Mark Searcey Skills & Research Interests

Medicinal chemistry

Top articles of Mark Searcey

Suramin: Effectiveness of analogues reveals structural features that are important for the potent trypanocidal activity of the drug

Experimental Parasitology

2024/5/1

Mark Searcey
Mark Searcey

H-Index: 14

Linda Troeberg
Linda Troeberg

H-Index: 21

Borylation via Iridium catalysed CH activation: a new concise route to duocarmycin derivatives

2024/4/24

Maria O'Connell
Maria O'Connell

H-Index: 26

Mark Searcey
Mark Searcey

H-Index: 14

Peptide inhibitors of the dyskerin/dyskerin protein-protein interaction, a cancer target highlighted by Dyskeratosis Congenita mutations in ribonucleoproteins of telomerase.

2024/3/20

Mark Searcey
Mark Searcey

H-Index: 14

Light-Activated Azobenzene Peptide Inhibitor of the PD-1/PD-L1 Interaction

2024/3/4

Mark Searcey
Mark Searcey

H-Index: 14

The development of potent, competitive CXCR4 antagonists for the prevention of cancer metastasis

Biochemical Pharmacology

2023/12/1

Mark Searcey
Mark Searcey

H-Index: 14

Anja Mueller
Anja Mueller

H-Index: 14

Junctions in DNA: underexplored targets for therapeutic intervention

2022/9/1

Mark Searcey
Mark Searcey

H-Index: 14

Structural basis of the negative allosteric modulation of 5-BDBD at human P2X4 receptors

Molecular pharmacology

2022/1/1

Taspine is a natural product that suppresses P2X4 receptor activity via phosphoinositide 3‐kinase inhibition

British journal of pharmacology

2021/12

David Richards
David Richards

H-Index: 2

Mark Searcey
Mark Searcey

H-Index: 14

Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds

Bioorganic & Medicinal Chemistry

2021/6/15

Laurence H Patterson
Laurence H Patterson

H-Index: 20

Mark Searcey
Mark Searcey

H-Index: 14

Amino DSA analogues as payloads for antibody-drug conjugates with multiple sites for conjugation. Initial studies and solid phase synthesis

Tetrahedron Letters

2021/5/25

Mark Searcey
Mark Searcey

H-Index: 14

Peptide directed phthalocyanine–gold nanoparticles for selective photodynamic therapy of EGFR overexpressing cancers

RSC Medicinal Chemistry

2021

Andrew Michael Beekman
Andrew Michael Beekman

H-Index: 9

Mark Searcey
Mark Searcey

H-Index: 14

A Peptide–Duocarmycin Conjugate Targeting the Thomsen-Friedenreich Antigen Has Potent and Selective Antitumor Activity

Bioconjugate Chemistry

2020/6/9

Andrew Michael Beekman
Andrew Michael Beekman

H-Index: 9

Mark Searcey
Mark Searcey

H-Index: 14

Synthetic analogues of ferulic acidexert anti-inflammatory and antioxidanteffects in human monocytic cells

British Journal of Pharmacology

2020/6

Active targeting of gold nanoparticles as cancer therapeutics

2020

Mark Searcey
Mark Searcey

H-Index: 14

See List of Professors in Mark Searcey University(University of East Anglia)

Co-Authors

academic-engine